La vendita allo scoperto per Roivant Sciences dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Roivant Sciences. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Roivant Sciences (NASDAQ:ROIV) Azioni, Report sulle vendite allo scoperto

Roivant Sciences

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Roivant Sciences Ltd

ROIVANT SCIENCES LTD WT EXP

News

GOEV

Canoo Announced Issuance Of 7,185,125 Shares At $0.3992 Each To Vendors For Services Rendered

Starting April 2025, patients suffering from chronic pain will have greater access to medical marijuana, according to a new decree from the Ministry of Health. Under the expanded access, general practitioners (GPs) in the country will be allowed to prescribe medical marijuana to registered patients with chronic pain, <a href="https://www.expats.cz/czech-news/article/czechia-takes-step-towards-laxer-cannabis-laws-with-new-bill">writes</a> Expats.
Ministry spokesperson Ondřej Jakob <a href="https://www.novinky.cz/clanek/domaci-ministerstvo-ustupuje-poptavce-po-konopi-na-bolest-ho-nove-predepisou-i-praktici-40498698">confirmed </a>to news outlets Novinky and Právo that the new rules are designed to simplify access."The decree allows GPs to prescribe medicinal cannabis for chronic, intractable pain."
Under the current law, only specialized doctors can prescribe cannabis, which is limiting for many patients. According to official data, roughly 8,000 people in the country use cannabis legally, but the demand is much higher. The National Drug Monitoring Center recently revealed results of its survey showing that about 600,000 Czechs use medical marijuana, and more than a million have tried it for self-treatment this year.
"It doesn't make sense that we can prescribe strong opiates like morphine but not medical cannabis," Dr. Petr Šonka, chairman of the Czech Association of General Practitioners, told Novinky. Šonka further stressed the importance of managing pain for terminal patients.
Furthermore, under the new rules, prescriptions will be valid for up to three months, and insurance will still cover 90% of the expense for up to 30 grams of marijuana per month. Coverage for cannabis extracts will also be expanded.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/41890759/polish-parliamentary-committee-sends-cannabis-decriminalization-petition-to-prime-minister">Polish Parliamentary Committee Sends Cannabis Decriminalization Petition To Prime Minister</a>
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
<h2 class="wp-block-heading">Proposal To Allow Cultivation And Possession</h2>
The expanded medical marijuana access follows up on the Czech <a href="https://www.benzinga.com/markets/cannabis/24/11/42043465/czech-government-legalizes-cultivation-of-three-cannabis-plants-allows-possession-of-50-grams">government's proposal</a> of a draft law that would reform&nbsp;criminal law regarding cannabis, with changes including relaxed rules on&nbsp;home cultivation and possession. The draft law now needs to be viewed by both chambers of Parliament.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/10/41295350/czech-senate-approves-restrictions-on-sale-of-kratom-and-hhc-products">Czech Senate Approves Restrictions On Sale Of Kratom And HHC Products</a></li>
</ul>
Photo: Benzinga edit with images by <a href="https://www.pexels.com/@rdne/">RDNE Stock project</a> and <a href="https://www.pexels.com/@jules-clark-624979041/">Jules Clark</a> via Pexels

Cannabis

Czech General Practitioners To Prescribe Medical Marijuana For Chronic Pain With Insurance Coverage Starting 2025

TD Cowen analyst Andrew Kligerman maintains Axis Capital Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXS#NYSE">AXS</a>) with a Buy and raises the price target from $118 to $127.

Price Target

Analyst Ratings

TD Cowen Maintains Buy on Axis Capital Holdings, Raises Price Target to $127

<ul>
<li>KODK</li>
<li>NVDA</li>
<li>MSTR</li>
<li>ACHR</li>
<li>DELL</li>
<li>RKLB</li>
<li>TSLA</li>
<li>CORN</li>
<li>AMZN</li>
<li>LOT</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment" title="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>

Trading Ideas

ACHR

AMZN

CORN

DELL

KODK

MSTR

NVDA

RKLB

TSLA

Top 10 Trending Stocks On WallStreetBets As Of November 27, 2024 (Via Swaggy Stocks)

B of A Securities analyst Vivek Arya maintains Ambarella (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMBA#NASDAQ">AMBA</a>) with a Underperform and raises the price target from $57 to $65.

AMBA

B of A Securities Maintains Underperform on Ambarella, Raises Price Target to $65

In the current session, the stock is trading at $22.09, after a 0.41% increase. Over the past month, Ares Capital Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCC#NASDAQ">ARCC</a>) stock increased by 3.09%, and in the past year, by 11.00%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2024/1732716911_0.png" alt="Past Year Chart" />

<h3>Ares Capital P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Ares Capital has a lower P/E than the aggregate P/E of 46.03 of the Capital Markets industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1732716911_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

ARCC

A Look Into Ares Capital Inc's Price Over Earnings

Barclays analyst Pablo Monsivais maintains Corporacion Inmobiliaria (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTMX#NYSE">VTMX</a>) with a Overweight and lowers the price target from $38 to $35.

VTMX

Barclays Maintains Overweight on Corporacion Inmobiliaria, Lowers Price Target to $35

Barclays analyst Adrienne Yih maintains Burlington Stores (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURL#NYSE">BURL</a>) with a Overweight and lowers the price target from $327 to $317.

BURL

Barclays Maintains Overweight on Burlington Stores, Lowers Price Target to $317

TD Cowen analyst Joshua Buchalter maintains Analog Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>) with a Buy and lowers the price target from $270 to $260.

TD Cowen Maintains Buy on Analog Devices, Lowers Price Target to $260

B of A Securities analyst Ronald Epstein maintains StandardAero (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SARO#NYSE">SARO</a>) with a Neutral and lowers the price target from $34 to $32.

SARO

B of A Securities Maintains Neutral on StandardAero, Lowers Price Target to $32

Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) shares closed slightly <a href="https://www.benzinga.com/quote/AAPL">higher on Tuesday</a>.
Apple is reportedly changing its approach to software updates. The tech giant appears to be opting for staggered rollouts of new features instead of bundling everything into annual iOS releases.
In his latest weekly &#8220;Power On&#8221; newsletter, Bloomberg columnist Mark Gurman said that Cupertino plans a significant update with iOS 18.4 <a href="https://www.benzinga.com/24/11/42183616/apple-could-delay-key-ios-19-features-plans-shifting-to-staggered-rollouts-with-2026-siri-overhaul-and-more">this spring</a>.
With the recent buzz around Apple, some investors may be eyeing potential gains from the company's dividends too. As of now, Apple offers an annual dividend yield of 0.43%, which is a quarterly dividend amount of 25 cents per share ($1.00 a year).
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $1,410,360 or around 6,000 shares. For a more modest $100 per month or $1,200 per year, you would need $282,072 or around 1,200 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($1.00 in this case). So, $6,000 / $1.00 = 6,000 ($500 per month), and $1,200 / $1.00 = 1,200 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
AAPL Price Action: Shares of Apple gained 0.9% to close at $235.06 on Tuesday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More:
<ul>
<li> <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/42188912/jim-cramer-linde-is-a-terrific-company-sees-another-stock-up-75-as-not-done">Jim Cramer: Linde Is A &#8216;Terrific&#8217; Company, Sees Another Stock Up 75% As &#8216;Not Done&#8217;</a></li>
</ul>
Image via Shutterstock

Long Ideas

AAPL

How To Earn $500 A Month From Apple Stock

Iris Energy Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) shares are trading higher Wednesday on the heels of the company&#8217;s first-quarter financial results. Multiple analysts raised price targets following the print. Here&#8217;s what <a href="https://www.benzinga.com/pressreleases/24/11/g42201221/iren-reports-q1-fy25-results">you need to know</a>.
What Happened: After the market close on Tuesday, Iris reported first-quarter Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) mining revenue of $49.6 million. The company reported a 28% increase in AI Cloud Services revenue quarter-over-quarter to $3.2 million. 
Adjusted EBITDA was $2.6 million in the quarter. The company said it mined 813 bitcoin in the period and ended the quarter with $98.6 million in cash and cash equivalents. Iris noted that it had $182.4 million in cash as of Oct. 31.
&#8220;We are pleased to report our Q1 FY25 results and reiterate our focus on low-cost Bitcoin mining, operating cashflows and shareholder returns,&#8221; said Daniel Roberts, co-founder and co-CEO of Iris Energy.
&#8220;We are just weeks away from achieving our 31 EH/s milestone and are excited to announce the acceleration of our growth trajectory to 50 EH/s in H1 2025, which was previously H2 2025.&#8221;
Iris said it had 21 EH/s installed in the quarter and remains on track to achieve 31 EH/s in December. The company currently has an all-in cash cost per bitcoin of approximately $29,000. Bitcoin was hovering around $94,000 at the time of publication, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Following the company&#8217;s quarterly results, Canaccord Genuity analyst Joseph Vafi maintained Iris with a Buy and raised the price target from $15 to $17. HC Wainwright &amp; Co. analyst Mike Colonnese maintained a <a href="https://www.benzinga.com/analyst-stock-ratings">Buy rating</a> and raised the price target from $13 to $16, and Needham analyst John Todaro reiterated a Hold rating. 
Check This Out: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42211674/bitcoin-at-93000-crash-or-pause-bullish-outlook-for-2025-says-10x-research">Bitcoin At $93,000—Crash Or Pause? &#8216;Bullish Outlook For 2025,&#8217; Says 10x Research</a>
IREN Price Action: Iris Energy shares were up 9.52% at $10.47 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Movers

$BTC

IREN

What's Going On With Bitcoin Mining Stock Iris Energy Wednesday?

Barclays analyst Michael Leithead maintains Berry Global Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BERY#NYSE">BERY</a>) with a Equal-Weight and raises the price target from $64 to $75.

BERY

Barclays Maintains Equal-Weight on Berry Global Gr, Raises Price Target to $75

POET Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POET#NASDAQ">POET</a>) shares are trading lower Wednesday after the company announced a $25 million <a href="https://www.benzinga.com/pressreleases/24/11/g42202419/poet-technologies-announces-us-25-million-registered-direct-offering">registered direct offering</a>.
What Happened: After the market close on Tuesday, POET Technologies announced that it expects to issue 5.55 million common shares and warrants exercisable for 2.78 million common shares.
The company said the combined price of one common share and the accompanying warrant will be $4.50. The warrant will be exercisable at $6 per common share for a period of five years from the date of issuance.
The offering is expected to close on or about Dec. 3. The company expects to raise gross proceeds of $25 million and will use any net proceeds for working capital related to its recently announced plans to <a href="https://www.benzinga.com/24/11/42168802/whats-going-on-with-poet-technologies-stock-monday">expand assembly operations</a> into Malaysia. 
POET Technologies offers high-speed optical engines, light source products and custom optical modules to the <a href="http://benzinga.com/topic/ai">AI</a> systems market and to hyperscale data centers.
See Also: <a href="https://www.benzinga.com/markets/equities/24/11/42211765/dragonfly-energy-sees-over-10-decline-as-new-smart-lithium-batteries-launch-amid-black-friday-event">Dragonfly Energy Sees Over 10% Decline As New Smart Lithium Batteries Launch Amid Black Friday Event</a>
<h3 class="wp-block-heading">How To Buy POET Stock</h3>
By now you're likely curious about how to participate in the market for POET Technologies &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. 
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
POET Price Action: POET shares were down 5.14% at $4.79 at the time of writing, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

POET

POET Technologies Stock Is Sliding Today: What's Happening?

Barclays analyst Luke Sergott maintains Agilent Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) with a Underweight and lowers the price target from $145 to $135.

Barclays Maintains Underweight on Agilent Technologies, Lowers Price Target to $135

BMO Capital analyst Michael Zaremski maintains Hartford Finl Servs Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIG#NYSE">HIG</a>) with a Market Perform and raises the price target from $100 to $141.

BMO Capital Maintains Market Perform on Hartford Finl Servs Gr, Raises Price Target to $141

Recent listings on Coinbase and Robinhood have invigorated bullish sentiment about Pepe, with traders calling for new all-time highs <a href="https://www.benzinga.com/money/pepe-price-prediction">to come soon.</a>
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Pepe (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>)</td>
<td>$0.00001833 </td>
<td>$7.7 Billion</td>
<td>&nbsp;+1.8%</td>
<td>&nbsp;-9.2%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.3934&nbsp;&nbsp;</td>
<td>$57.8 Billion</td>
<td>&nbsp;+4%</td>
<td>&nbsp;+0.99%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00002499</td>
<td>$14.7 Billion</td>
<td>&nbsp;+4.2%</td>
<td>&nbsp;+1.9%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Crypto trader MaxBecauseBTC sees Pepe standing out in the meme coin space, predicting it will join Dogecoin and Shiba Inu as multi-billion-dollar assets. 
In a <a href="https://x.com/MaxBecauseBTC/status/1861644070910820549">post</a> on X on Tuesday, he emphasized that while most meme coins will fade quickly, Pepe&#8217;s enduring appeal could establish it as a key player in the market.
Max highlights a potential "flight to quality" among investors, moving away from weaker meme coins toward those with stronger speculative value. This shift, he suggests, could lead to a rapid repricing of high-potential assets like Pepe.
Similarly, trader Dami-Defi predicted a "massive breakout" for Pepe in the near future, further cementing its position among top-tier meme coins.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Smart money is accumulating <a href="https://twitter.com/search?q=%24PEPE&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$PEPE</a>! Massive breakout coming soon &#x270d;&#xFE0F; <a href="https://t.co/8UA5qDR6TT">pic.twitter.com/8UA5qDR6TT</a>
&mdash; Dami-Defi (@DamiDefi) <a href="https://twitter.com/DamiDefi/status/1861699007208472723?ref_src=twsrc%5Etfw">November 27, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Statistics: IntoTheBlock data shows large transaction volume increasing by 187.3% and daily active addresses down by 7.2%. Transactions greater than $100,000 remain relatively flat at 446. 
Around 86% of Pepe holders are currently making profit.
Community News: In mid-November, Coinbase <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41945111/pepe-listed-on-robinhood-coinbase-reaches-new-all-time-high-on-44-gain-traders-speculate-about-dogecoin-like-run">listed Pepe on its exchange</a>. 
Robinhood also announced the listing of Pepe on its platform thereby expanding its coverage to a broader U.S. audience.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42097462/dogecoin-millionaire-shares-50-million-meme-coin-strategy-for-2025-pepe-brett-are-this-bull-runs-doge-shiba-inu">&#8216;Dogecoin Millionaire&#8217; Shares $50 Million Meme Coin Strategy For 2025: Pepe, Brett Are This Bull Run&#8217;s DOGE, Shiba Inu</a></li>
</ul>
Image: Shutterstock

$DOGE

$PEPE

$SHIB

Pepe Set to Join Dogecoin, Shiba Inu As Multi-Billion Dollar Meme Coin By 2025: 'Massive Breakout' Coming Soon, Trader Predicts

BMO Capital analyst Keith Bachman maintains CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) with a Outperform and raises the price target from $315 to $380.

CRWD

BMO Capital Maintains Outperform on CrowdStrike Holdings, Raises Price Target to $380

WIIM

SOS Ltd. shares are trading higher after the company announced that its board of directors approved a $50 million investment to purchase Bitcoin.

FRSX

Foresight's Eye-Net Mobile Subsidiary Signs Agreement With Software République To Integrate And Conduct Testing Of Eye-Net's 'vehicle-to-everything' Collision Avoidance Solution

Reports Q2 revenue $4.47M vs $3.648M last year. "I am pleased to finish out another quarter with continued clinical execution, including positive d...

Roivant Sciences reports Q2 EPS (31c), consensus (26c)

Roivant Sciences Ltd. 2025 Q2 - Results - Earnings Call Presentation

Roivant Sciences Ltd. 2024 Q2 - Results - Earnings Call Presentation

Roivant Sciences Ltd. (ROIV) Q2 2024 Earnings Call Transcript

TD Cowen analyst Yaron Werber maintained a Buy rating on Roivant Sciences (ROIV – Research Report) yesterday. The company's shares closed yesterday...

TD Cowen Keeps Their Buy Rating on Roivant Sciences (ROIV)

Leerink Partners analyst David Risinger has reiterated their bullish stance on ROIV stock, giving a Buy rating yesterday. David Risinger has given ...

Positive Outlook on Roivant Sciences: Buy Rating Justified by Strong Cash Position and Promising Pipeline Developments

JPMorgan's 'Analyst Focus List' – growth, income, value, short ideas

JPMorgan updates its U.S. Analyst Focus List – Adds TPR, ALRM, REG

Vertex leads J.P. Morgan's top biotech picks list for 2025

Wall Street Lunch: Holiday-Shortened Week Starts Positively

ABBV

AGCO

ALRM

ARMK

ASND

AVGO

BACRP

BPMC

BRBR

CVNA

CYBR

DAWN

DKNG

EWTX

GWRE

IMVT

ISRG

KLAC

KVUE

LEGN

MNDY

MSFT

NTRA

PODD

PTCT

REGCO

REGCP

ROIV

RVMD

SCHW

SIRI

SNDX

SPGI

SWTX

TFII

TMUS

TRGP

TVTX

ULTA

VERA

VICI

VRTX

XENE

Press Releases

H.C. Wainwright Announces 26th Annual Global Investment Conference, September 9-11, 2024. Event Features Leading Industry Keynote Addresses by Vivek Ramaswamy, Michael Saylor; Bitcoin Panel Moderated by Anthony Scaramucci.

Health Care

Roivant Provides Update on Graves' Disease Development Program

General

Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress

Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024

Earnings

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update

Comments

Roivant Sciences

Vendite allo scoperto

Roivant Sciences (NASDAQ:ROIV) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO